- Home
- VRAR vs ITRM Comparison
VRAR vs ITRM Comparison
Compare VRAR & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- ITRM
- Stock Information
- Founded
- VRAR 2016
- ITRM 2015
- Country
- VRAR United States
- ITRM Ireland
- Employees
- VRAR N/A
- ITRM N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- ITRM Health Care
- Exchange
- VRAR Nasdaq
- ITRM Nasdaq
- Market Cap
- VRAR 42.4M
- ITRM 49.5M
- IPO Year
- VRAR 2021
- ITRM 2018
- Fundamental
- Price
- VRAR $1.55
- ITRM $1.49
- Analyst Decision
- VRAR Strong Buy
- ITRM Strong Buy
- Analyst Count
- VRAR 1
- ITRM 1
- Target Price
- VRAR $4.67
- ITRM $5.00
- AVG Volume (30 Days)
- VRAR 316.7K
- ITRM 635.0K
- Earning Date
- VRAR 02-13-2025
- ITRM 02-07-2025
- Dividend Yield
- VRAR N/A
- ITRM N/A
- EPS Growth
- VRAR N/A
- ITRM N/A
- EPS
- VRAR N/A
- ITRM N/A
- Revenue
- VRAR $9,230,197.00
- ITRM N/A
- Revenue This Year
- VRAR $39.02
- ITRM N/A
- Revenue Next Year
- VRAR N/A
- ITRM $160.88
- P/E Ratio
- VRAR N/A
- ITRM N/A
- Revenue Growth
- VRAR N/A
- ITRM N/A
- 52 Week Low
- VRAR $0.50
- ITRM $0.81
- 52 Week High
- VRAR $7.00
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- VRAR 39.84
- ITRM 46.16
- Support Level
- VRAR $1.55
- ITRM $1.42
- Resistance Level
- VRAR $1.73
- ITRM $1.58
- Average True Range (ATR)
- VRAR 0.18
- ITRM 0.11
- MACD
- VRAR -0.01
- ITRM 0.02
- Stochastic Oscillator
- VRAR 10.58
- ITRM 61.76
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.